Emerging new drugs for wound repair.
Every year, millions of people experience burns, suffer from nonhealing wounds, or have acute wounds that become complicated by infection, dehiscence or problematic scarring. Effective wound treatment requires carefully considered interventions often requiring multiple clinic or hospital visits. The resulting costs of wound care are staggering, and more efficacious and cost-effective therapies are needed to decrease this burden. Unfortunately, the expenses and difficulties encountered in performing clinical trials have led to a relatively slow growth of new treatment options for the wound management. Research efforts attempting to examine wound pathophysiology have been hampered by the lack of an adequate chronic wound healing model, and the complexity of the wound healing cascade has limited attempts at pharmacological modification. As such, currently available wound healing therapies are only partially effective. Therefore, many new therapies are emerging that target various aspects of wound repair and the promise of new therapeutic interventions is on the immediate horizon.
Meier
Karen
K
S-2221 MCN Vanderbilt School of Medicine, Nashville, TN 37232, USA.
Nanney
Lillian B
LB
D001704:Biopolymers / Q000627:therapeutic use; D002483:Cellulose, Oxidized / Q000627:therapeutic use; D003094:Collagen / Q000627:therapeutic use; D004270:DNA, Circular / Q000627:therapeutic use; D017719:Diabetic Foot / Q000188:drug therapy / Q000473:pathology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology / Q000627:therapeutic use; D015316:Genetic Therapy; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use; D006133:Growth Substances / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010957:Plasmids / Q000627:therapeutic use; D003668:Pressure Ulcer / Q000188:drug therapy / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D014647:Varicose Ulcer / Q000188:drug therapy / Q000473:pathology; D042442:Vascular Endothelial Growth Factors / Q000494:pharmacology / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects*
D001704:Biopolymers; D002483:Cellulose, Oxidized; D004270:DNA, Circular; D006133:Growth Substances; C100666:KCB-1 protein, recombinant; D011994:Recombinant Proteins; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003094:Collagen